Combined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice
- Design
- Animal study · Intermediate outcome
- Match to healthy normal-weight adults aged 55–75
- Not human evidenceVERY_INDIRECT: the subjects are female Swiss mice made obese over 10 weeks, not people; section 1 rule 4 makes animal evidence VERY_INDIRECT.
- Could weight loss explain it?
- Not applicablenot_applicable: the outcomes the record is built on, body weight, adiposity and whole-body insulin sensitivity, are weight, body composition and glycaemic measures themselves, so whether weight loss explains them is not a question (IN-062). The fall in liver fat is an outcome weight loss is known to improve and the record does not separate it from the accompanying weight loss, so no independent mediation claim is made for it either.
- Study tier
- Study tier 4VERY_LOW: a preclinical study in female Swiss mice, which section 3 rates VERY_LOW. The abstract gives no group sizes, no estimates, no confidence intervals and no p values, and the allocation of animals to groups and any blinding are not described.
- Assessment
- Version 3 · Checked against the source by AI · Nov 6, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
Female Swiss mice were made obese over 10 weeks, then treated for 8 weeks with subcutaneous tirzepatide, a 12 h feeding window, resistance training as stair climbing, or combinations of these. Tirzepatide reduced body weight gain and feed efficiency and lowered adipose mass and adipocyte hypertrophy; combined with the feeding window and resistance training it accelerated weight loss, bringing body weight close to control levels, and resistance training increased skeletal muscle mass. Tirzepatide with the feeding window improved glucose tolerance, and all the interventions reduced liver fat, with no additional hepatic benefit from combining them. This is an animal study and the abstract reports no group sizes and no statistics of any kind.
01Findings
What the study reported
- Drugs
- Tirzepatide
- Treatment duration
- 8 weeks
- Route
- subcutaneous
- Comparator
- control mice, and time-restricted feeding or resistance training given alone or combined with tirzepatide
- Primary outcome
- adiposity and whole-body insulin sensitivity, with body weight
- Effect
- No numerical results are given. Tirzepatide reduced body weight gain and feed efficiency; combined with time-restricted feeding and resistance training it accelerated weight loss, bringing body weight close to control levels; adipose mass and adipocyte hypertrophy fell; resistance training improved strength and increased skeletal muscle mass; tirzepatide with time-restricted feeding improved glucose tolerance; all interventions reduced hepatic lipid accumulation, with no additional hepatic benefit from combining them.
- 95% confidence interval
- not reported in abstract
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- An animal study in female Swiss mice made obese over 10 weeks and treated for 8 weeks, reporting body composition, glucose tolerance, strength and liver fat with no group sizes and no statistics of any kind; allocation and blinding are not described, and the combination arms are not separated from the drug's own effect.
Who was studied
- Sex distribution
- female mice only
- Obesity status
- required: obesity induced over 10 weeks before treatment
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- induced obesity in female Swiss mice
- Inclusion exclusion
- female Swiss mice after 10 weeks of obesity induction
Study quality details
- Study design
- Preclinical (animal)
- Sample size
- not extracted
- Randomization
- not reported in abstract
- Blinding
- not stated
- Comparator
- control mice, and time-restricted feeding or resistance training given alone or combined with tirzepatide
- Follow up duration
- not stated
- Outcome type
- intermediate
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- VERY_INDIRECT
- Statistical precision
- no CI or p-value reported in the abstract; number of animals not stated
- Risk of bias
- not assessed
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- Coordination for the Improvement of Higher Education Personnel; Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors with potent effects on body weight regulation, glucose homeostasis and metabolic health. However, its interaction with dietary and exercise interventions as well as its impact on obesity and hepatic metabolic pathways, particularly in females, remain unclear. Here, we tested whether tirzepatide, alone or combined with time-restricted feeding (TRF) or resistance training, modulates energy balance, strength performance, adipose tissue remodelling, insulin sensitivity and hepatic lipid accumulation in female mice. Female Swiss mice after 10 weeks of obesity induction were treated with tirzepatide, TRF or resistance training for 8 weeks. Tirzepatide was administered subcutaneously using a dose-escalation protocol. TRF consisted of a 12 h feeding window, and resistance training was performed as stair climbing on alternating days. Body weight, caloric intake and feed efficiency were monitored longitudinally. Glucose homeostasis was assessed by intraperitoneal glucose and insulin tolerance tests. Adipose depots, skeletal muscle and liver mass were quantified, and hepatic lipid accumulation was evaluated by histology and RT-qPCR of lipogenic metabolism genes. Tirzepatide reduced body weight gain and feed efficiency, consistent with a negative energy balance. When combined with TRF and resistance training, tirzepatide accelerated weight loss, and the addition of resistance training further enhanced this effect, bringing body weight close to control levels. These effects were associated with reduced adipose mass and adipocyte hypertrophy, indicating improved adipose tissue remodelling. Resistance training improved strength performance and increased skeletal muscle mass. Tirzepatide combined with TRF, with or without resistance training, improved glucose tolerance in female mice. All interventions reduced hepatic lipid accumulation. Collectively, tirzepatide, particularly in combination with TRF and resistance training, exerts enhanced metabolic benefits on obesity, insulin sensitivity and metabolic regulation in female mice. KEY POINTS: Tirzepatide combined with time-restricted feeding and resistance training produced greater reductions in body weight and adiposity in obese female mice. Combined interventions improved whole-body insulin sensitivity more effectively than isolated strategies. Resistance training preserved skeletal muscle mass during tirzepatide-induced weight loss. All interventions similarly reduced hepatic lipid accumulation and lipogenic gene expression. Tirzepatide-based therapies enhanced systemic metabolic health without additional hepatic benefits from combined interventions.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Nov 1, 2026 | 42958899 first ingestion |
| pubmed | Nov 1, 2026 | 42958899 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| funding-repair | Nov 6, 2026 | funding_source: 'not reported in abstract' -> 'Coordination for the Improvement of Higher Educa'. IN-067: funding_source, industry_funded and manufacturer re-derived from PubMed's grants metadata, which PASS-SPEC did not admit as a source until v1.3, so the review had replaced a named funder with a placeholder. Judgments, population, effects, prose and conflicts fields are unchanged. Owner decision IN-067 option 1, 2026-11-06. |
| pubmed | Nov 8, 2026 | 42958899 duplicate matched on doi |
| pubmed | Nov 8, 2026 | 42958899 duplicate matched on doi |